LWAC
GSK icon

Laurel Wealth Advisors (California)’s GSK GSK Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,936
Closed -$214K – 637
2022
Q2 		$214K Buy
3,936
+51
+1% +$2.81K 0.02% 615
2022
Q1 		$212K Sell
3,885
-333
-8% -$18.1K 0.02% 702
2021
Q4 		$233K Sell
4,218
-633
-13% -$32.9K 0.02% 704
2021
Q3 		$232K Sell
4,851
-375
-7% -$18.8K 0.04% 404
2021
Q2 		$260K Buy
5,226
+111
+2% +$5.33K 0.03% 433
2021
Q1 		$228K Buy
5,115
+8
+0.2% +$363 0.03% 416
2020
Q4 		$235K Buy
5,107
+243
+5% +$11.2K 0.03% 394
2020
Q3 		$229K Hold
4,864
– – 0.04% 365
2020
Q2 		$248K Buy
4,864
+41
+0.9% +$2.1K 0.05% 326
2020
Q1 		$228K Sell
4,823
-114
-2% -$6.08K 0.05% 332
2019
Q4 		$290K Sell
4,937
-4,476
-48% -$249K 0.05% 351
2019
Q3 		$502K Buy
9,413
+2,393
+34% +$123K 0.09% 249
2019
Q2 		$351K Sell
7,020
-134
-2% -$6.72K 0.08% 277
2019
Q1 		$374K Sell
7,154
-10,640
-60% -$532K 0.09% 249
2018
Q4 		$849K Sell
17,794
-1,324
-7% -$65.2K 0.25% 104
2018
Q3 		$960K Buy
19,118
+227
+1% +$11.5K 0.24% 104
2018
Q2 		$951K Sell
18,891
-296
-2% -$14.9K 0.25% 101
2018
Q1 		$937K Sell
19,187
-3,667
-16% -$171K 0.29% 89
2017
Q4 		$1.01M Sell
22,854
-307
-1% -$14.2K 0.29% 89
2017
Q3 		$1.18M Buy
23,161
+955
+4% +$48.5K 0.39% 79
2017
Q2 		$1.2M Buy
22,206
+558
+3% +$29.7K 0.43% 74
2017
Q1 		$1.14M Sell
21,648
-1,393
-6% -$70.7K 0.44% 70
2016
Q4 		$1.11M Buy
23,041
+3,153
+16% +$156K 0.49% 61
2016
Q3 		$1.07M Sell
19,888
-849
-4% -$46.5K 0.51% 61
2016
Q2 		$1.12M Sell
20,737
-777
-4% -$40.9K 0.54% 58
2016
Q1 		$1.09M Sell
21,514
-1,840
-8% -$91.6K 0.55% 52
2015
Q4 		$1.18M Buy
+23,354
New +$1.19M 0.61% 45

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Laurel Wealth Advisors (California)'s GSK Position: Q3 2022 in Review

Laurel Wealth Advisors (California) sold out of GSK (GSK) in Q3 2022, closing a stake of 3,936 shares — an estimated $214K sold.

Laurel Wealth Advisors (California) first reported a position in GSK in Q4 2015 and held it in 27 quarters. The position peaked at $1.2M in Q2 2017. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

  • Laurel Wealth Advisors (California) reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
  • Laurel Wealth Advisors (California) sold 3,936 GSK shares in Q3 2022, an estimated $214K.
  • Laurel Wealth Advisors (California) first reported a position in GSK in Q4 2015 and held it in 27 quarters.
  • Laurel Wealth Advisors (California)'s GSK position peaked at $1.2M in Q2 2017.
  • 742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q3 2022, filed 14 Nov 2022.